SZShumin Zhou

Shumin Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shumin Zhou has a total of 115 co-authors. Here are the top co-authors by number of shared publications:

  • Qingcheng Yang

    Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

    6 shared publications
  • Sheng-Ce Tao

    Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China

    5 shared publications
  • Yu Miao

    Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

    4 shared publications
  • Shu-Juan Guo

    Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, China

    3 shared publications
  • Ting Yuan

    Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

    3 shared publications
  • Yang Wang

    Institute of Microsurgery on Extremities, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

    3 shared publications

Latest Publications

  • Open Access

    Advances in Bone-on-a-Chips for In Vitro Modeling of Bone Physiology and Pathology

    by Xiuyun Cheng, Mingxia Lu, Ming Ma, Shumin Zhou, Jun Xu, Yuhao Li, Hongxu Lu

    Bone is a dynamic and multifunctional tissue that provides mechanical support, regulates mineral homeostasis, supports hematopoiesis, and relies on complex interactions among multiple cell types. The increasing incidence of bone-related diseases, such as osteoporosis, osteoarthritis, fracture non-union, and bone cancer, highlights the need for in vitro models that better reflect human bone physiology. Bone-on-a-chip technology, developed through advances in microfluidics, biomaterials, and tissue engineering, offers a promising approach to recreate key features of the bone microenvironment in vitro. By incorporating bone-mimicking materials, relevant bone cells, vascular components, fluid perfusion, and mechanical stimulation, these platforms allow more realistic investigation of bone remodeling, regeneration, disease mechanisms, and drug responses. In parallel, bone organoids and their integration with microfluidic chips have further expanded the capabilities of in vitro bone models by enabling the formation of self-organized, human-relevant bone tissues with increased cellular complexity. This review summarizes recent progress in bone-on-a-chip systems, including models for osteogenesis and bone regeneration, vascularized bone, bone marrow and hematopoietic niches, cancer bone metastasis, and mechanobiological studies. Key design principles, materials, cellular components, and applications in disease modeling, drug screening, toxicity assessment, and personalized medicine are discussed. Current challenges and future directions are also discussed to support the continued development of more physiologically relevant in vitro bone models.


  • Open Access

    Integrin αVβ5 regulates myoblast proliferation and differentiation in sarcopenia mice treated with FNDC5 gene delivery

    by Guoxi Gao, Qiyang Wang, Yuqiong Zhang, Minghong Shao, Yiming Liang, Shumin Zhou, Sheng Lu

    Background: Irisin which is encoded by FNDC5 gene, has emerged as a promising therapeutic candidate for alleviating sarcopenia; however, its long-term therapeutic application in muscle regeneration remains insufficiently developed. Methods: Our study investigated the potential of FNDC5 gene delivery in both cellular and animal levels via a virus vector. It was indicated that FNDC5 overexpression promoted myoblast proliferation while inhibiting myogenic differentiation, and vice versa. Mechanistically, we confirmed that the product of FNDC5 gene, irisin binds to integrin αVβ5 on the cell membrane of myoblasts, leading to activation of the downstream FAK/SRC complex using coimmunoprecipitation (co-IP) and confocal microscopy. RNA-Seq and qPCR analyses revealed that irisin exposure activated genes related to the extracellular matrix (ECM) and its ligands, thereby promoting the cell cycle and enhancing the proliferation of myoblast. Additionally, treatment with the integrin αVβ5 inhibitor cilengitide enhanced myogenic differentiation but suppressed cell proliferation, highlighting the crucial role of integrin αVβ5 in determining myoblasts’ cell fate. Furthermore, in sarcopenia mouse models, AAV-mediated FNDC5 supplementation activated integrin αVβ5-related signaling as expected, resulting in increased muscle mass and alleviation of sarcopenia symptoms. Results: Our findings demonstrate that integrin αVβ5 acts as a key switch in regulating the proliferation and differentiation of myoblasts under FNDC5 gene delivery. When integrin αVβ5 is active, FNDC5 over-expression enhances cell proliferation rather than differentiation. Conversely, when integrin αVβ5 is inhibited, FNDC5 over-expression promotes myogenic differentiation over proliferation. Moreover, the binding of irisin to integrin αVβ5 induces the expression of ECM proteins in myoblasts and activates the Bgn-TLR4 signaling pathway, which further enhances cell proliferation. This FNDC5-ITGAVB5-FAK-mTOR-Bgn-TLR4 signaling axis was also validated in a sarcopenia mouse model. Conclusion: Integrin αVβ5 is a critical regulator of myoblast proliferation and differentiation in response to FNDC5 gene supplement. These findings provide new insights into FNDC5 biological functions and suggest potential therapeutic strategies for enhancing muscle regeneration and treating sarcopenia.


  • Open Access

    Cancer IDO1‐Mediated Tryptophan–Kynurenine Metabolic Reprogramming to Drive Skeletal Muscle Atrophy and Cachexia Acceleration

    by Leng Han, Lingjie Jing, Xinting Zhu, Ciqin Li, Lu Bai, Yang Fang, Yuxuan Zhou, Dingyuan Bai, Jin Lu, Yonglong Han, et al.

    Background: Cancer cachexia is a debilitating syndrome characterized by severe skeletal muscle wasting, which significantly impairs patient quality of life and survival. Indoleamine 2,3‐dioxygenase 1 (IDO1), a key enzyme in tryptophan (Trp) metabolism, is often upregulated in cancers, but its specific role in driving lung cancer–associated cachexia remains inadequately defined. This study investigated the mechanistic role of Ido1 in cancer cachexia and evaluated the therapeutic potential of its inhibition. Methods: We established Lewis lung carcinoma (LLC) models in C57BL/6 mice using wild‐type, Ido1 ‐overexpressing ( Ido1 ‐OE) and Ido1 ‐knockout ( Ido1 ‐KO) cells. Muscle mass, tumour growth and metabolic changes were assessed in vivo. Transcriptomic and targeted metabolomic analyses were performed on muscle and serum samples. In vitro, we examined the effects of tumour‐conditioned media, the Trp metabolite kynurenine (Kyn) and Trp supplementation on C2C12 myotube atrophy. In vivo experiments verified the efficacy of the Ido1 inhibitor palmatine hydrochloride (PAL). Molecular pathways were analysed via western blot and qPCR. Results: Compared to LLC mouse models, Ido1 ‐OE significantly exacerbated tumour growth and cachexia, leading to a significant decrease in lean body weight, gastrocnemius and tibialis anterior muscle weights ( p < 0.01, p < 0.0001, p < 0.001). Gastrocnemius muscle fibre cross‐sectional area significantly decreased in the Ido1 ‐OE group ( p < 0.0001). Transcriptomic analysis revealed that Ido1‐ OE activated pro‐inflammatory and protein degradation pathways (upregulating MuRF1/Atrogin1, p < 0.05) while suppressing anabolic signalling pathways (oestrogen pathways, p < 0.01). Metabolomics analysis revealed unique metabolic signatures in Ido1 ‐OE mice: Trp depletion and Kyn accumulation. In vitro experiments demonstrated that Ido1‐ OE enhanced LLC cell proliferation and migration capabilities ( p < 0.0001, p < 0.0001). Tumour‐conditioned medium (TCM) derived from Ido1 ‐OE tumours significantly induced C2C12 myotube atrophy ( p < 0.01). Similarly, direct treatment with Kyn led to dose‐dependent muscle fibre shrinkage, with significant atrophy observed at 30 μM ( p < 0.01) and 100 μM ( p < 0.0001). Notably, the myotube atrophy induced by Kyn was significantly reversed by the addition of supplemental Trp ( p < 0.0001). Compared with the Ido1 ‐OE group, PAL treatment reduced gastrocnemius and tibialis anterior atrophy ( p < 0.01; p < 0.05). Mechanistically, PAL inhibited the mRNA expression levels of MuRF1/Atrogin1 ( p < 0.0001, p < 0.001), as well as their corresponding protein levels ( p < 0.0001, p < 0.0001). Furthermore, PAL restored the phosphorylation level of mTOR ( p < 0.001), as well as the mRNA expression of myosin heavy chain ( p < 0.01). Conclusions: Our findings demonstrate that Ido1 accelerates muscle atrophy and cancer cachexia by driving a metabolic reprogramming centred on the Trp–Kyn pathway. Pharmacological inhibition of Ido1 with PAL effectively mitigates these effects, positioning Ido1 as a promising therapeutic target for treating cancer cachexia.


  • Open Access

    Therapeutic efficacy of oncolytic adenovirus YSCH-01 in osteosarcoma evaluated in PDX and CDX mouse models

    by Hanqiang Jin, Ruoyu Chen, Yonggang Wang, Jin Huang, Xue-Ping Cao, Hafiz Khuram Raza, Xian-Long Fang, Kang-Jian Zhang, Ning Li, Shumin Zhou, et al.

    YSCH-01, a recombinant L-IFN oncolytic adenovirus based anticancer drug with dual anti-tumor effects, has displayed significant antitumor properties in cancer treatment. However, its specific role in osteosarcoma and the underlying mechanisms remain under studied. Therefore, we analyzed clinical samples and performed experiments using osteosarcoma cell lines in both in vitro and in vivo settings. At the RNA and protein levels, the expression of L-IFN gene carried by YSCH-01 showed the potential antitumor properties. RNA-seq analysis of tumor samples treated with YSCH-01 provided insights into the altered gene expression profiles and signaling pathways, shedding light on the molecular basis of its antitumor effects. Those findings demonstrated that YSCH-01 displayed dose-dependent infectivity with different levels of efficacy and a significant inhibition of osteosarcoma cell proliferation. In both cell line and patient derived xenograft models, YSCH-01 exhibited potent therapeutic effects with the activated type I interferon signaling pathway in tumor tissues, particularly in terms of its distant effects. Furthermore, this study found out the key signal pathways through which YSCH-01 exerts its antitumor effects in osteosarcoma, which pinpointed potential therapeutic targets by identifying the type I interferon signaling pathway as the candidate molecular markers and their correlation with patient outcomes, positioning YSCH-01 as a promising candidate for osteosarcoma treatment.

  • Open Access

    Deciphering disease through glycan codes: leveraging lectin microarrays for clinical insights

    by Hangzhou Yang, Zihan Lin, Bo Wu, Jun Xu, Sheng-Ce Tao, Shumin Zhou

    Glycosylation, a crucial posttranslational modification, plays a significant role in numerous physiological and pathological processes. Lectin microarrays, which leverage the high specificity of lectins for sugar binding, are ideally suited for profiling the glycan spectra of diverse and complex biological samples. In this review, we explore the evolution of lectin detection technologies, as well as the applications and challenges of lectin microarrays in analyzing the glycome profiles of various clinical samples, including serum, saliva, tissues, sperm, and urine. This review not only emphasizes significant advancements in the high-throughput analysis of polysaccharides but also provides insight into the potential of lectin microarrays for diagnosing and managing diseases such as tumors, autoimmune diseases, and chronic inflammation. We aim to provide a clear, concise, and comprehensive overview of the use of lectin microarrays in clinical settings, thereby assisting researchers in conducting clinical studies in glycobiology.


  • Open Access

    ANGPTL4 negatively regulates the progression of osteosarcoma by remodeling branched-chain amino acid metabolism

    by Shanyi Lin, Yu Miao, Xu Zheng, Yang Dong, Qingcheng Yang, Quanjun Yang, Silin Du, Jun Xu, Shumin Zhou, Ting Yuan

    Angiopoietin-like-4 (ANGPTL4), a secreted glycoprotein that is mainly known as a regulator in lipid metabolism, now, is also indicated to be involved in the regulation of cancer progression and metastasis. However, little is known about not only biological functions, but also underlying mechanism of ANGPTL4 in the progression of osteosarcoma (OS). Here, we discovered that ANGPTL4 is downregulated in OS, and is associated with branched-chain amino acid (BCAA) metabolism. The BCAAs (valine, leucine, and isoleucine) are essential amino acids that play an important role in metabolic regulation. Aberrant BCAA metabolism is also found in various cancers and is associated with tumor progression, including proliferation, invasion, and metastasis. In this study, we indicated that the negative relation between the expression of ANGPTL4 and BCAA catabolism in OS samples and cell lines. The knockdown of ANGPTL4 in OS cells resulted in the accumulation of BCAAs, which in turn activated the mTOR signaling pathway, enhancing OS cell proliferation. Thus, reduced expression of ANGPTL4 is associated with the progression of OS. Taken together, our results demonstrated that the ANGPTL4/BCAA/mTOR axis is an important pathway in OS progression and may be a potential therapeutic target to slow OS progression.


  • Open Access

    Alpha-(1,6)-fucosyltransferase (FUT8) affects the survival strategy of osteosarcoma by remodeling TNF/NF-κB2 signaling

    by Shanyi Lin, Lenian Zhou, Yang Dong, Qingcheng Yang, Quanjun Yang, Hanqiang Jin, Ting Yuan, Shumin Zhou

    Glycosylation is an important modification of membrane proteins that results in functional changes in many cellular activities, from cell-cell recognition to regulatory signaling. Fucosyltransferase 8 (FUT8) is the sole enzyme responsible for core fucosylation, and aberrant fucosylation by dysregulated expression of fucosyltransferases is responsible for the growth of various types of carcinomas. However, the function of FUT8 in the progress of osteosarcoma (OS) has not been reported. In this study, we found that FUT8 is expressed at lower levels in patients with OS and in human OS cell lines such as MNNG/HOS, U2OS, and 143B, suggesting that attenuated expression of FUT8 is involved in the growth and progression of OS. Mechanistically, FUT8 affects the survival strategy of OS by modifying core-fucosylation levels of TNF receptors (TNFRs). Lower fucosylation of TNFRs activates the non-canonical NF-κB signaling pathway, and in turn, decreases mitochondria-dependent apoptosis in OS cells. Together, our results point to FUT8 being a negative regulator of OS that enhances OS-cell apoptosis and suggests a novel therapeutic strategy for treating OS.


  • Open Access

    The “sugar‐coated bullets” of cancer: Tumor‐derived exosome surface glycosylation from basic knowledge to applications

    by Shanyi Lin, Shumin Zhou, Ting Yuan

    Scientific interest in exosomes has exploded in recent decades. In 1990 only three articles were published on exosomes, while over 1,700 have already been published half‐way into 2020.1 While researchers have shown much interest in exosomes since being discovered in 1981, an appreciation of the potential role of glycans in exosome structure and function has emerged only recently. Glycosylation is one of the most common post‐translational modification, which functions in many physiological and pathological aspects of cellular function. Many components of exosomes are heavily glycosylated including proteins, lipids, among others. Thus, glycosylation undoubtedly has a great impact on exosome biosynthesis and function. Despite the importance of glycosylation in exosomes and the recent recognition of them as biomarkers for not only malignancies but also other system dysfunction and disease, the characterization of exosome glycans remains understudied. In this review, we discuss glycosylation patterns of exosomes derived from various tissues, their biological features, and potential for various clinical applications. We highlight state‐of‐the‐art knowledge about the fine structure of exosomes, which will allow researchers to reconstruct them by surface modification. These efforts will likely lead to novel disease‐related biomarker discovery, purification tagging, and targeted drug transfer for clinical applications in the future.


  • Open Access

    Yb3+-containing chitosan hydrogels induce B-16 melanoma cell anoikis via a Fak-dependent pathway

    by Yu Miao, Jiawei Lu, Junhui Yin, Changchun Zhou, Yaping Guo, Shumin Zhou

    Melanoma is the most lethal dermal tumor, and a high recurrence rate and skin defects are two main serious problems. An antimelanoma material,which effectively inhibits tumor recurrence and possesses excellent biocompatibility, is urgently needed to treat melanoma. In this study, we developed a novel antitumor Yb3+ [Yb(NO3)3]containing chitosan hydrogel (Yb-CS hydrogel) by dissolving Yb(NO3)3 and chitosan in acetic acid solution and forming composite hydrogels by a freeze-drying process after adding NaOH to the mixed solution. In vitro studies demonstrated that the Yb3+ produces effect of inducing cell death in Yb-CS hydrogel. Moreover, we found that the Yb-CS hydrogel inhibited a focal adhesion kinase (FAK)-dependent signaling pathway and induced B-16 cell anoikis. However, the Yb-CS hydrogel was less effective on L929 normal mouse dermal cells. In vivo studies showed that the Yb-CS hydrogel inhibited the recurrence of melanoma in a mouse bare xenograft tumor model. We concluded that the Yb-CS hydrogel could potentially be used in the antimelanoma field, especially in the inhibition of melanoma recurrence.


  • Overexpressed N-fucosylation on the cell surface driven by FUT3, 5, and 6 promotes cell motilities in metastatic pancreatic cancer cell lines

    by Hui-Feng Gao, Qi-Yang Wang, Ke Zhang, Lian-Yu Chen, Chien-Shan Cheng, Hao Chen, Zhi-Qiang Meng, Shu-Min Zhou, Zhen Chen